Clinical practice: AHF as a consequence of ACS (Dimitrios Farmakis, Athens, Greece)

How would you treat a 64-year old male with a history of coronary heart disease, hypertension and diet-controlled type 2 diabetes? The patient also has evolving anterior myocardial infarction and is Killip Class II. Dr Dimitrios navigates through the treatment journey discussing when and why the patient received levosimendan and what data supports this. Learn how the beneficial effects of this calcium selective inotrope may be related to its additional pleiotropic effects and discover more about its safety profile. Dr Dimitrios concludes his presentation by summarising four key advantages of using levosimendan for the treatment of AHF or CS as a consequence of ACS.

 

Videos (5)
Login/ Register Maximise Minimise